Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series.

Carlo TortiMaria MazzitelliFederico LonghiniEugenio GarofaloAndrea BruniAida GiancottiGiorgio Settimo BarrecaAngela QuirinoMaria Carla LibertoFrancesca SerapideGiovanni MateraEnrico Maria TrecarichiPaolo Navalesinull null

Published in: BMC infectious diseases (2019)

IV zanamivir could be a good therapeutic option in patients with severe influenza A(H1N1)pdm09 infection who are unable to take oral or aerosolised antiviral medication. We recommend prospective randomized control trials to support this hypothesis.

Keyphrases

early onset
double blind
open label
healthcare
high dose
placebo controlled
phase iii
randomized controlled trial
clinical trial
drug induced
adverse drug